Current Report Filing (8-k)
October 17 2016 - 4:24PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 17, 2016
RESPIRERX
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
1-16467
|
|
33-0303583
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S
Employer
Identification No.)
|
126
Valley Road, Suite C
Glen
Rock, New Jersey
|
|
07452
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
7.01 Regulation FD Disclosure
On
October 17, 2016, RespireRx Pharmaceuticals Inc. (the “Company”) announced that the Company’s President, Chief
Executive Officer and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present at the BIO Investor Forum
on Tuesday, October 18, 2016 at 11:00 a.m. Pacific Time (2:00 p.m. Eastern Time). The Forum is being sponsored by the Biotechnology
Innovation Organization and is being held at the St. Francis Hotel in San Francisco, California, on October 18 and 19, 2016.
The
slide presentation that Dr. Manuso will be using at the conference is attached as Exhibit 99.1 and is being furnished and not
filed pursuant to Item 7.01 of Form 8-K. A copy of the slide deck will also be available by clicking on the investors tab on the
Company’s web-site (www.respirerx.com) and following the links and instructions.
The
press release announcing the Company’s participation in the conference is attached as Exhibit 99.2.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
A
list of exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere
in this document, and is incorporated herein by reference.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
October 17, 2016
|
RESPIRERX PHARMACEUTICALS INC.
|
|
|
|
|
By:
|
/s/
Robert N. Weingarten
|
|
|
Robert
N. Weingarten
|
|
|
Vice
President and Chief Financial Officer
|
EXHIBIT
INDEX
Exhibit
Number
|
|
Exhibit
Description
|
99.1
|
|
Slide
Presentation*
|
99.2
|
|
Press
Release dated October 17, 2016*
|
*
Furnished herewith.
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Apr 2023 to Apr 2024